108 related articles for article (PubMed ID: 11090961)
1. Gene expression of GLUT isoforms and VHL in oral squamous cell carcinoma.
Fukuzumi M; Hamakawa H; Onishi A; Sumida T; Tanioka H
Cancer Lett; 2000 Dec; 161(2):133-40. PubMed ID: 11090961
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
3. Expression of facilitative glucose transporter isoforms in human brain tumors.
Nagamatsu S; Sawa H; Wakizaka A; Hoshino T
J Neurochem; 1993 Dec; 61(6):2048-53. PubMed ID: 8245960
[TBL] [Abstract][Full Text] [Related]
4. Expression of glucose transporters in human peritoneal mesothelial cells.
Schröppel B; Fischereder M; Wiese P; Segerer S; Huber S; Kretzler M; Heiss P; Sitter T; Schlöndorff D
Kidney Int; 1998 May; 53(5):1278-87. PubMed ID: 9573543
[TBL] [Abstract][Full Text] [Related]
5. Human rhabdomyosarcoma cells retain insulin-regulated glucose transport activity through glucose transporter 1.
Ito S; Nemoto T; Satoh S; Sekihara H; Seyama Y; Kubota S
Arch Biochem Biophys; 2000 Jan; 373(1):72-82. PubMed ID: 10620325
[TBL] [Abstract][Full Text] [Related]
6. Differences in the expression of glucose transporter protein isoforms in human retinoblastoma cell lines.
Tsukamoto H; Mishima H; Hirata K; Sato E; Kurokawa T; Ishibashi S
Jpn J Ophthalmol; 1997; 41(4):226-30. PubMed ID: 9304435
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of glucose transporters in normal and pathologic thyroid tissue.
Matsuzu K; Segade F; Matsuzu U; Carter A; Bowden DW; Perrier ND
Thyroid; 2004 Oct; 14(10):806-12. PubMed ID: 15588375
[TBL] [Abstract][Full Text] [Related]
8. Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues.
Binder C; Binder L; Marx D; Schauer A; Hiddemann W
Anticancer Res; 1997; 17(6D):4299-304. PubMed ID: 9494524
[TBL] [Abstract][Full Text] [Related]
9. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
10. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis.
Richards FM; Schofield PN; Fleming S; Maher ER
Hum Mol Genet; 1996 May; 5(5):639-44. PubMed ID: 8733131
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
Knebelmann B; Ananth S; Cohen HT; Sukhatme VP
Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397
[TBL] [Abstract][Full Text] [Related]
12. Expression of facilitative glucose transporter 1 mRNA in colon cancer was not regulated by k-ras.
Noguchi Y; Okamoto T; Marat D; Yoshikawa T; Saitoh A; Doi C; Fukuzawa K; Tsuburaya A; Satoh S; Ito T
Cancer Lett; 2000 Jun; 154(2):137-42. PubMed ID: 10806301
[TBL] [Abstract][Full Text] [Related]
13. Role of nuclear and cytoplasmic localization in the tumour-suppressor activity of the von Hippel-Lindau protein.
Lewis MD; Roberts BJ
Oncogene; 2003 Jun; 22(26):3992-7. PubMed ID: 12821933
[TBL] [Abstract][Full Text] [Related]
14. Renal cell carcinoma development in the rat independent of alterations at the VHL gene locus.
Walker C; Ahn YT; Everitt J; Yuan X
Mol Carcinog; 1996 Feb; 15(2):154-61. PubMed ID: 8599582
[TBL] [Abstract][Full Text] [Related]
15. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.
Schoenfeld A; Davidowitz EJ; Burk RD
Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8817-22. PubMed ID: 9671762
[TBL] [Abstract][Full Text] [Related]
16. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional regulation of glucose transporters in human oral squamous cell carcinoma cells.
Paolini R; Moore C; Matthyssen T; Cirillo N; McCullough M; Farah CS; Botha H; Yap T; Celentano A
J Oral Pathol Med; 2022 Sep; 51(8):679-683. PubMed ID: 35920070
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells.
Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M
Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066
[TBL] [Abstract][Full Text] [Related]
19. Role of the von Hippel-Lindau tumour suppressor protein in the regulation of HIF-1alpha and its oxygen-regulated transactivation domains at high cell density.
Paltoglou SM; Roberts BJ
Oncogene; 2005 May; 24(23):3830-5. PubMed ID: 15750626
[TBL] [Abstract][Full Text] [Related]
20. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation.
Iliopoulos O; Ohh M; Kaelin WG
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):11661-6. PubMed ID: 9751722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
